You are here


Software for Modeling Delivery and Penetration of Antibody Conjugates

Primary tabs

The National Cancer Institute (NCI) seeks parties interested in licensing software for the targeted delivery of anti-cancer agents in solid tumors.
NIH Reference Number
Product Type
  • Drug Design
  • Anti-Cancer Modeling
  • Tumor Delivery
  • Dosing
  • Tumor Penetration
Collaboration Opportunity
This invention is available for licensing.
Description of Technology

The National Cancer Institute (NCI) seeks parties to license software for modeling the targeted delivery of anti-cancer agents in solid tumors.

The software models the permeability and concentration of intravenously administered antibody anti-cancer agent conjugates in solid tumors.  The models can be used to determine optimal dosing regimen of a therapeutic in a particular cancer type.  Thirty factors that affect delivery rates and efficiencies are analyzed as variables in generating the models.

Potential Commercial Applications
  • Drug design
  • Combination therapy
  • Personalized medicine
Competitive Advantages
  • Accurate permeability modeling of anti-cancer therapeutics.
Development Stage

R.K. Jain et al. Delivery of molecular and cellular medicine to solid tumors. [PMID 11259838]

G.M. Thurber et al. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. [PMID 18541331]

Y. Pak et al. Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors. [PMID: 22562466]

K.C. Chen et al. Modeling recombinant immunotoxin efficacies in solid tumors. [PMID: 18183487]

Patent Status
  • Research Material: NIH will not pursue patent prosecution for this technology
Therapeutic Area
Thursday, June 7, 2018